Marcello Arca
Catania, Italy
University of Rome Sapienza. He completed his research training as postdoctoral fellow at the Center for Human Nutrition and then at the Department of Molecular Genetics, at the UT Southwestern Medical Center in Dallas, Texas (USA). He is full professor of Internal Medicine and, at present, he Chair of the Department of Translational and Precision Medicine: He is also the Director the Unit of Internal Medicine and Metabolic Diseases as well as the Unit of Rare Lipid Disorders at the University Hospital Policlinico Umberto I in Rome.
The research interests of Prof. Arca are related to genetic disorders of lipid metabolism, to genetics of atherosclerosis and to treatment of cardiovascular risk. He is co-authors of 300 papers in peer reviewed journal and 10 chapters of books. He is member of the Editorial Board of Endocrine and American Journal of Preventive Medicine and he is serving as reviewer for several scientific journals in the area of metabolism, cardiovascular disease, genetics and internal medicine. At present, he is holding the chair of President of the Italian Society of Atherosclerosis (SISA)
Monday 23 May
HoFH : where do we stand?
- Philippe Moulin
-
Frederick Raal
Frederick Raal
Johannesburg, South AfricaProfessor Raal is currently Professor and Head of the Division of Endocrinology and Metabolism, as well as Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
He has authored or co-authored over 300 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, and Atherosclerosis. He is on the Editorial Board of Atherosclerosis and is a Board member of the International Atherosclerosis Society.
Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidaemia, particularly heterozygous and homozygous familial hypercholesterolaemia (FH). The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and ANGPTL3-inhibitors in this patient group.
